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Abstract
INTRODUCTION: In 2015, smoking prevalence in Republic of Macedonia was 36% in men and 21% in women 
We aim to assess the effectiveness and cost-effectiveness of two methods of motivating smokers to quit smoking 
compared with very brief advice (VBA) alone. Тo date, there are no studies investigating smoking cessation treatment 
in Republic of Macedonia.
METHODS/DESIGN: RCT with process evaluation and cost-effectiveness analysis within 31 general practices in 
Republic of Macedonia recruiting smokers currently smoking >10 cigarettes per day, aged >35 years, attending 
primary care practices for any reason, regardless of motivation to quit smoking. Respondents will be randomized into 
one of three groups: (1) VBA and assessment and communication of lung age; (2) VBA and additional assessment 
and communication of exhaled carbon monoxide (CO) levels; or (3) control group – VBA. All participants who attempt 
to quit smoking will be offered behavioral support based on the UK standard program for smoking cessation.  Primary 
outcome: Proportion of smokers who are quit at 4 weeks (7-day point prevalence, confirmed by salivary cotinine 
level).  Secondary outcomes: Proportion who have attempted to quit smoking or have quit smoking, a proportion 
that has reduced the number of cigarettes and motivation to quit smoking; cost-effectiveness analysis calculating 
cost per quality-adjusted life year. We will evaluate the fidelity to the intervention and will explore patients’ and GPs’ 
experience and the acceptability of the study intervention by interview.
DISCUSSION: The study will evaluate the effectiveness of combining feedback about lung age or exhaled CO levels 
with VBA and support for smoking cessation in primary care compared to giving VBA and support alone. It will explore 
how willing primary care physicians are to perform such interventions and the acceptability and effectiveness of such 
interventions to patients in Republic of Macedonia.
TRIAL REGISTRATION: The study is registered on the ISRCTN registry (ISRCTN54228638).
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Introduction
Smoking is the leading cause of chronic 
disease and is the primary cause of mortality and 
morbidity in industrialized countries [1], [2]. Cigarette 
smoke affects not only smokers but also non-smokers; 
passive smoking can cause respiratory conditions, 
cancer, and heart disease [1].
The health benefits of quitting are well 
established. With few exceptions, the future risk 
is reduced when smokers stop smoking and 
continues to decrease while smoking-abstinence is 
maintained [3], [4], [5]. Progression of smoking-related 
illnesses is also slowed and life expectancy improves 
by an average of 10 years if people quit before the 
age of 40 [6]. For these reasons, smoking cessation 
interventions are central to many disease prevention 
strategies.
Republic of Macedonia has a long tradition 
of consuming tobacco. In 2015, smoking prevalence 
in Republic of Macedonia was 36% in men and 21% 
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in women. Tobacco control legislation in Republic of 
Macedonia includes the introduction of plain packaging, 
bans on advertising and a ban on smoking in public 
places, but no smoking cessation programs are offered, 
and pharmacotherapy is limited in availability due to high 
costs [7]. However, from 2017, two international projects 
were rolled out in Republic of Macedonia to support 
smoking cessation. Both were funded from the Global 
Bridges project and involved training small groups of 
physicians to train other physicians to offer very brief 
advice (VBA) to tobacco dependent patients. The first 
involved secondary and tertiary care doctors [8] and the 
second primary care physicians [9], this latter project was 
led by the Centre for Family Medicine at Saints Cyril and 
Methodius University of Skopje, Republic of Macedonia 
(CFM). The GPs in this latter project recognized the 
lack of cessation support available for smokers, so 
undertook training in behavioral support from the UK 
National Centre for smoking cessation training [10]. This 
behavioral support is provided by the GPs themselves 
and consists of five consultations over 8–12 weeks. The 
GP practices participating in this trial will begin offering 
VBA with behavioral support for those who wish to quit 
smoking as standard care when the trial commences.
Much research has investigated the 
effectiveness of various smoking cessation aids, 
particularly in high-income countries [11]. Brief advice 
from doctors and other health professionals has been 
shown to promote smoking cessation compared to no 
intervention (pooled estimated odd ratio 1.66; 95% 
confidence interval [CI] 1.42–1.94), with quit rates 
around 4% in patients unselected by motivation to quit 
smoking [12]. Quit rates are higher with more intensive 
behavioral interventions and/or with pharmacotherapy 
support [11]. Nicotine replacement therapy (NRT) is 
not cheap in Republic of Macedonia and alternative 
methods to promote smoking cessation need to be 
tested. Health reasons and the development of a 
chronic disease is a common motivator for patients to 
consider quitting [13]. Thus, presenting smokers with 
personalized evidence of the harmful effects of smoking 
might encourage them to quit [14].
A Cochrane systematic review found 
insufficient evidence of the effectiveness of several 
prompts (spirometry, partner support, and lung function 
feedback) in boosting quit rates [15]. However, two 
potential types of biomedical risk information that 
may promote quitting are lung age (LA) and exhaled 
carbon monoxide (CO). LA [16] is a biomarker which 
is easily understood and demonstrates to patients the 
premature lung damage suffered as a consequence of 
smoking. Although feedback of LA is recommended by 
some guidelines (e.g., Lung Foundation Australia) [17] 
for motivating smokers to quit, existing published 
trials are heterogeneous in design and results are 
inconsistent [18]. CO is a toxic gas inhaled by smokers that 
bind with greater affinity than oxygen to hemoglobin in 
the blood, compromising the transport of oxygen around 
the body and increasing the cardiovascular risk [19]. 
Measuring the level of CO in exhaled breath is quick, 
relatively inexpensive, and non-invasive. Similar to 
LA, a number of studies have tested the effectiveness 
of giving feedback on CO as a motivator for smoking 
cessation [20], [21], [22], [23], but the results are 
equivocal [15]. Previous trials of both the effectiveness 
of providing LA or exhaled CO have also rarely been 
conducted in low resource settings where there is limited 
established support such as in Republic of Macedonia.
Through links with the International Primary 
Care Respiratory Group (IPCRG), the CFM has joined 
with the University of Birmingham (UoB) National 
Institute for Health Research Global Health Research 
Group on Global chronic obstructive pulmonary disease 
(COPD) in primary care, breathe well. Given the 
introduction of training to GPs to offer VBA for smoking 
cessation in Republic of Macedonia, we propose testing 
the effectiveness and cost-effectiveness of adding 
feedback on LA or exhaled CO to VBA in comparison 
with VBA alone in unselected smokers in primary care 
(i.e., smokers will be included in the study regardless 
of their motivation to quit smoking). Drawing on the 
Medical Research Council (MRC) guidance [24] for 
process evaluation in randomized controlled trials of 
complex interventions, a process analysis will also be 
conducted to inform interpretation of the trial results, 
and to understand context specific issues around 
acceptability of delivering the interventions.
Methods
Aims and objectives
Study aims
1. Assess the effectiveness of combining 
feedback about LA or exhaled CO levels 
with VBA and support for smoking cessation 
compared to giving VBA and support alone
2. Conduct a process evaluation informed 
by MRC process evaluation guidance to 
understand: (a) Fidelity by GPs in delivery 
of the intervention, (b) acceptability to GPs 
of delivering the intervention, (c) participant 
understanding, acceptability, and responses to 
the intervention
3. Estimate the cost-effectiveness of both 
interventions compared with VBA and support 
alone.
Design
A randomized controlled trial of three 
alternative methods of motivating smokers to quit 
smoking conducted within GP practices in Republic of 
Macedonia (Figure 1).
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Participants
Eligible participants will be recruited from 
approximately 31 primary care practices in Skopje 
and surrounding areas of Republic of Macedonia. GP 
practices will commence recruitment in four phases 
allowing adjustment of processes if necessary. 
Smokers consulting their GP for any reason and who 
fit the eligibility criteria, regardless of motivation to quit 
smoking, will be invited to take part, given a patient 
information leaflet, and asked to sign written consent. 
Anonymized data will also be collected from each GP 
practice on key characteristics of eligible patients who 
choose not to participate: Age, sex, and number of 
cigarettes smoked per day.
Eligibility criteria
Inclusion criteria
The following criteria were included in the 
study.
• Smoking >10 cigarettes (manufactured or roll 
up) per day
• Age >35 years.
Exclusion criteria
The following criteria were excluded from the 
study.
• Deemed unsuitable to participate in the trial by 
GP, for example, cognitive impairment, recent 
bereavement, and terminal illness
• Standard contraindications for spirometry [25]
• Previously received VBA to quit smoking
• Currently using e-cigarettes or NRT.
Randomization and allocation to trial arm
Allocation to the trial arm will occur when 
consented patients are registered on the database 
and the “randomize” option selected. A simple 
Usual GP consultation 
GP consents patient 
to trial RANDOMISATION
1. VBA
ASKADVISE, ACT
2. VBA with CO
measurement and
feedback
ASK, ADVISE, ACT
3. VBA with LA
measurement and
feedback
ASK, ADVISE, ACT
If patient wishes to
quit ACT:
GP: discusses and
sets quit date within
a week of
randomization
Quit date:
GP provides 1st
behavioral support
visit
Quit date +1 week:
GP provides 2nd
behavioral support
visit
Quit date + 2
weeks:
GP provides 3rd
behavioral support
visit
Quit date + 4
weeks: GP provides
4rd behavioral
support visit
Quit date + 8-12
weeks: GP provides
5th behavioral
support visit
CO
measurement
in second arm 
T=4 Weeks post randomisation
Questionnaire + salivary cotinine test
Recording of selected GP VBA consultations for each trial arm
Qualitative interviews
with patients and GPs
T=12 Weeks post randomization
Questionnaire + salivary cotinine test
T=26 Weeks post randomization
Questionnaire +salivary cotinine test
 Figure 1: Flow chart of the study
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randomization sequence will be computer generated 
by a statistician, stratified by GP practice, and will 
allocate participants in a ratio of 1:1:1. Allocation will 
be revealed to the GP and patient after completion of 
the baseline questionnaire.
Interventions
LA with VBA and support to quit smoking 
(VBA + LA)
In the LA intervention arm (VBA + LA), 
GPs will explain to patients that smoking can cause 
accelerated lung function decline and that this can 
be understood in terms of “lung age.” GPs will also 
explain that smoking cessation slows down the rate 
of lung function decline, although it cannot repair the 
damage that is already done. GPs will assess LA 
using a hand held spirometer (Vitalograph COPD-
6). This is a simple device which needs little training 
to administer and provides a measure of forced 
expiratory volume (FEV)1 and FEV6 as a proxy 
for forced vital capacity [20]. Three blows will be 
undertaken without the use of bronchodilators and the 
lowest LA, as displayed by the Vitalograph COPD-6 
machine, will be fed back to the patient by the GP 
with explanation. If LA is equal to or less than the 
individual’s chronological age, they will be informed 
that the test result is normal but they will be advised 
that it is still important to stop smoking before the 
damage is done. If LA is greater than chronological 
age, they will be given the “lung age” in years and be 
advised that although they cannot reverse the damage 
quitting smoking will prevent further damage. This will 
be combined with VBA for smoking cessation to all, 
with support to quit smoking for those who choose to 
attempt quitting (as described in the control arm).
Exhaled CO with VBA and support to quit 
smoking (VBA + CO)
In the exhaled CO intervention arm (VBA + 
CO), GPs will explain to patients that cigarette smoke 
contains CO and at high concentrations is toxic, 
displacing oxygen in the blood, compromising oxygen 
transportation, and increasing cardiovascular risk. 
GPs will assess exhaled CO using a Bedfont piCO 
Smokerlyzer, a simple device needing little training to 
administer and giving parts per million (ppm) of CO in 
exhaled breath. Participants hold their breath for 15 s 
and blow into the device which provides a reading. The 
GP will report the CO level, explaining the implications. 
This will be combined with VBA for smoking cessation, 
with support to quit smoking for those choosing to 
attempt quitting (as described in the control arm). 
Participants wishing to quit in this arm will have their 
exhaled CO repeated and fed-back at each support 
session.
VBA alone and support to quit smoking (VBA 
only)
GPs will deliver VBA. This includes “Asking” a 
patient’s smoking status, “Advising” current smokers to 
quit smoking, and “Acting” to set up appropriate support 
to quit for patients wanting to make a quit attempt (Box).
GPs will:
• Ask: Confirm smoking status
• Advise
 • About the harms of smoking
 • Benefits of quitting
 • To stop smoking and the best 
way to stop
• Act
 •  For participants not wanting 
to quit smoking, GPs will 
advise that the offer of 
support remains open should 
they want to take it up another 
time
 •  For participants wanting to 
quit smoking, the GP will assist 
the patient with a quit plan 
including: Quit date, advice 
on how to deal with cravings/
withdrawal and a plan for 
support (pharmacological 
and behavioral)
  •  All participants (regardless of 
quit intention) will receive a 
smoking information leaflet.
For participants who want to quit smoking, 
GPs will offer behavioral support adapted from the UK 
standard treatment program for smoking cessation 
published by the National Centre for Smoking Cessation 
Training [10], with sessions at quit date, then 1, 2, 4, and 
8-12 weeks post-quit date. During these visits, patients 
will receive advice about medication, how to deal with 
cravings and withdrawal symptoms, and behavioral 
support. Citizen (Tabex) medication is available in 
Republic of Macedonia, but is expensive and patients 
have to pay for it themselves. Another NRT is only 
available if purchased online or in neighboring countries.
Outcomes
The primary outcome of the study will be:
1. Proportion of smokers who are quit at 
4 weeks (7-day point prevalence confirmed 
salivary cotinine level of: (1) <10 ng/ml, or (2) 
<100 ng/ml for those who report exposure to 
second hand cigarette smoke in the home on 
a daily basis, or (3) ≥10 ng/ml in those who 
E - Public Health Public Health Disease Control
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report using NRT/e-cigarettes at any time point 
during the study, irrespective of exposure to 
second hand cigarette smoke)
The secondary outcomes of the study will be:
2. Proportion who have attempted to quit smoking 
measured at 4, 12, and 26 weeks
3. Proportion who have quit smoking at 4, 12, and 
26 weeks (7-day point prevalence, self-report 
only)
4. Proportion who have quit smoking at 12 and 
26 weeks (7-day point prevalence self-reported 
abstinence, confirmed as primary outcome)
5. Proportion who have reduced the number of 
cigarettes, they smoke per day at 4, 12, and 
26 weeks
6. Motivation to quit at 4, 12, and 26 weeks
7. Cost per additional quitter at 4 weeks
8. Cost per quality-adjusted life year (QALY) 
gained at 26 weeks
Process outcomes:
9. Acceptability to the GPs of delivering the 
intervention
10. Acceptability, understanding, and response to 
the intervention of participants
11. Fidelity to the delivery of the intervention.
Acknowledging that the validity of smoking 
abstinence confirmation using cotinine testing may be 
limited when patients are using nicotine replacement 
products or are exposed to secondhand smoke; in a 
sub-sample, we will compare abstinence as defined in 
the primary and secondary outcomes with the following 
additional definitions:
1. Proportion who have quit smoking at 4, 12, 
and 26 weeks confirmed with CO monitor tests 
(7-day point prevalence self-reported abstinence 
with an exhaled CO reading of >10 ppm). To 
avoid influencing quit rates, the results will be 
concealed from participants unless a reading 
has already been taken earlier that day
2. Proportion who are quit at 4, 12, and 26 weeks 
(7-day point prevalence self-reported 
abstinence) with a narrower time window (past 
4 days) for reported exposure confirmed with 
salivary cotinine level of:
 a. <10 ng/ml, or
 b.  <100 ng/ml for those who report 
exposure to second hand cigarette 
smoke indoors in the past 4 days, or
 c.  ≥10 ng/ml in those who report using 
NRT/e-cigarettes in the past 4 days, 
irrespective of exposure to second 
hand cigarette smoke.
Sample size
Few published studies report the effectiveness 
of LA or exhaled CO in combination with VBA to quit 
smoking, and none of these studies have been conducted 
in Republic of Macedonia. Only one study testing, the 
effectiveness of LA in combination with VBA is available 
that reports quit rates at 1 month (which is the primary 
outcome of our study), and this was conducted in 
Ireland [18]. Based on this study, we originally powered 
our study to detect a difference of 10% in the primary 
outcome between the control and each intervention arm 
at 4 weeks (12% VBA vs. 22% VBA + LA vs. 22% VBA 
+ CO). At 90% power and a significance level of 5%, 
this required a sample size of 885 participants in total 
(295 participants per arm). However, after consideration 
by the trial steering committee (TSC), the sample size 
calculation was revised based on a lower proportion of 
quits in each arm and a 5% difference between arms, 
as the number of participants attempting to quit was 
much lower than anticipated and it became apparent 
that the Irish study findings may not be generalizable to 
the Macedonian population. To detect a difference of 5% 
in the primary outcome between the control and each 
intervention arm at 4 weeks (3% VBA vs. 8% VBA + LA 
vs. 8% VBA + CO) with 90% power and a significance 
level of 2.5%, we will recruit 1182 participants in total 
(394 participants per arm).
Data collection
The following data will be collected:
Study assessment visit 1 (Baseline)
Participants will complete a baseline 
questionnaire including sociodemographic information 
(gender, age, ethnicity, education, employment status 
and income level, residence [rural/urban], and marital 
status) and smoking related information (average 
cigarettes per day, smoking history, Fagerstrom test for 
nicotine dependence [26], motivation to quit smoking, 
previous attempts to quit smoking, and second-hand 
smoke exposure).
GPs will complete the further information 
on the duration of assessment visit, delivery of VBA 
components, CO reading/LA reading (depending on 
trial arm), quit intention following intervention and quit 
date if relevant, and motivation to quit using motivation 
to stop smoking scale immediately post VBA [27].
Study assessment visit 2-4 (4, 12, and 
26 weeks follow-up)
Participants will attend follow-up visits to 
collect outcome data. If unable to attend, data will be 
collected over the telephone. Participants will self-
report current smoking status and length of time since 
last cigarette smoked, number of quit attempts, number 
of cigarettes or other tobacco products used over the 
past week (per day or per week), motivation to quit 
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smoking (self-reported questionnaire) [27], use of any 
smoking cessation aids, cost of any smoking cessation 
aids used, and exposure to second-hand smoke (living 
or working with smoker(s)).
Abstinence from those reporting having quit 
smoking will be confirmed by measuring salivary 
cotinine using NicAlert test strips in the GP practice.
Process evaluation
Recording of consultations
To assess the fidelity of the intervention 
delivery, participants’ consultations will be audio-
recorded for 2–3 weeks while both recruitment and 
behavioral support visits are occurring. Two baseline 
and behavioral support visits from each arm per GP 
will be assessed for time required for, and GP fidelity 
to deliver VBA or support, and additional CO or LA 
components.
Qualitative interviews
A purposive sample of patients and GPs will be 
invited to participate in one-to-one interviews exploring 
their views on the trial and barriers and enablers to 
smoking cessation advice and support in general. 
Patients who have consented to participate will be 
interviewed after their 4-week follow-up appointment. 
GPs will be interviewed once they have completed 
recruitment. Interviews will be semi-structured, lasting 
30–60 min, either face-to-face or over the phone, 
recorded, and transcribed. Participants will be sampled 
to represent a range of characteristics (GPs: Practice 
location, number of participants recruited, and age. 
Patients: Gender, age, and quit status at 4 weeks). 
Data will be collected until saturation has been reached 
(around 10–15 GPs and 10–15 patients from each 
intervention arm) [28]. Transcripts will be anonymized 
and all identifiable information removed.
Data analysis
Effectiveness analysis
Baseline characteristics will be reported 
as simple descriptive statistics. For the primary and 
secondary outcomes that are proportions, we will 
calculate RR (95% CI) using a Poisson model with robust 
standard errors adjusting for the stratification variables of 
the center with a random effect. In accordance with the 
Russell Standard [29], we will conduct an intention to treat 
analysis and assume those lost to follow-up are smokers.
Cost-effectiveness analysis
An incremental cost-effectiveness analysis will be 
undertaken to calculate the cost per additional quitter at 
4 weeks for both interventions, with a cost-utility analysis 
also undertaken to calculate cost per QALY gained over 
6 months, using data from the EQ-5D-5L questionnaire [30]. 
Data on all health-care resources required to deliver 
the intervention will be collected during the trial and any 
additional costs incurred either by the health services or 
the patient to assist with quitting smoking (e.g., additional 
prescriptions). The Macedonian version of the EQ-5D-5L 
will also be given to patients to complete at baseline, 4, 
12, and 26 weeks. Sensitivity analysis will be performed on 
key assumptions made.
Qualitative analyses
Interview data will be analyzed using the 
framework approach [28]. Data coding will consist of 
a hybrid deductive-inductive approach and analyst 
triangulation carried out on 10% of interviews while 
developing the thematic framework.
Data management
Data will be collected on case report forms 
and participant questionnaires which will be kept in a 
locked cabinet in a secure location at the GP practice 
for 5 years. A copy will also be transferred and held at 
the Centre for Family Medicine, where it will be kept in 
a locked filing cabinet.
Case report forms and questionnaire data will 
be entered electronically onto a bespoke REDCap online 
database either by the GP or by the research team. 
The database will be accessed remotely by GPs or the 
research team and will be held on UoB computer servers.
Audio data from GP consultations and patient 
or GP interviews will be recorded on a Dictaphone and 
transferred onto a secure local computer server at the 
CFM as soon as possible. Anonymized transcripts may 
be transferred to the UoB for analytic triangulation.
Trial oversight
The study will be overseen by a TSC, 
consisting of one representative from each of the 
following stakeholder groups: Patient, clinician/policy 
maker, International Scientific Advisory Committee 
(ISAC), research team, and the Breathe Well executive 
committee. An additional representative from the ISAC 
will chair. Meetings will take place every 6–12 months 
as required. As this is a low risk trial, a separate Data 
Monitoring Committee will not be convened; rather the 
functions of this committee will be carried out by the TSC.
Regulatory issues
Ethics approval
Ethical permission to conduct the study has 
been granted by the ethics committees at Saints 
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Cyril and Methodius University, Skopje, Republic of 
Macedonia (UKUM034/95) and UoB (ERN_18-12408).
Consent
If the patient chooses to take part in the research 
study, the GP will set aside time, after the patient’s 
appointment, to discuss the study with the patient, and 
any questions or concerns about the information sheet, 
study, or participation. No financial remuneration was 
offered for participation.
If the patient is happy to proceed, the GP will go 
through the consent process and complete the consent 
form in conjunction with the patient and collect the 
questionnaire. The questionnaire will not be collected 
in patients who decline to take part in the research 
study. Patients can withdraw participation in the study 
at any time without giving any reasons and without their 
medical rights being affected.
Participants will be given the option to be 
contacted in the future regarding other related studies or 
studies in the Breathe Well program. Information about 
this will also be clearly stated within the participant 
information sheet, which will explain that in particular 
some participants may be contacted to participate in a 
one-to-one interview to discuss their experiences and 
acceptability of the intervention. Participants will be 
advised that there is no obligation for them to provide 
permission for this section of the consent form.
Sponsorship and Indemnity
Sponsorship and indemnity will be provided by 
Dr. Labachevski Nikola MD, Ph.D., who is the director 
of the Institute of Preclinical and Clinical Pharmacology 
with Toxicology, Medical Faculty, Saints Cyril and 
Methodius University of Skopje. All research sites will 
have a risk assessment and monitoring plan as guided 
by the risk assessment.
Confidentiality
All members of the research team have 
completed Good Clinical Practice training. No 
personal information will be passed on to any third 
parties. All study participants will be assigned a study 
ID number. No identifiable data will be used on any 
research documents. Study data will be stored on 
a REDCap database, hosted on a UoB encrypted 
server which follows the General Data Protection 
Regulation.
Paper-based data will be stored in locked filing 
cabinets at the GP sites, with copies in locked filing 
cabinets at the CFM. Electronic data from the process 
evaluation and fidelity monitoring will be held securely 
on encrypted laptops and an encrypted server at the 
CFM. Data at the CFM will be stored in line with UoB 
policy for a minimum of 10 years after study completion. 
GP practice sites will hold the research data for a 
minimum of 5 years.
Discussion
This research is the first of its kind to be 
conducted in the Republic of Macedonia. It will explore 
the effectiveness and cost-effectiveness of combining 
feedback about LA or exhaled CO levels with VBA 
and support for smoking cessation in primary care 
compared to giving VBA and support alone. It will 
explore how willing primary care physicians are to 
perform such interventions and the acceptability and 
effectiveness of such interventions to patients in 
Republic of Macedonia.
Dissemination Policy
Results of the study will be disseminated 
through academic peer-reviewed publications and at 
relevant national/international academic conferences.
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